Alliances
Amgen and Kirin have decided to dissolve their joint venture, Kirin-Amgen.
Astra signed a licensing deal with Mereo BioPharma to out license the oral inhibitor of neutrophil elastase to the smaller Mereo.
Versartis has retained Cowen to assist in evaluating its strategic options.
Merck released its third-quarter financial results today, and along with it a hint--just a hint--that there might be some M&A deals in the future.
Incyte picked up MGA012 and the exclusive rights to develop the drug worldwide.
AbbVie announced a strategic collaboration with Alector to develop and commercialize drugs for ALZ’s disease and other neurodegenerative disorders.
Despite the failures of late stage ALZ’s drugs developed by numerous companies, Biogen seems confident in the future of its amyloid plaque targeting aducanumab.
The former Biogen CEO is making waves at his new venture, Vir Biotechnology.
Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra.
Shares of Arcturus are up nearly 15 percent in Thursday morning trading after the company inked a collaboration agreement with Janssen Pharma to develop a hepatitis B drug program.
PRESS RELEASES